Just read about this in a daily newsletter I get. Something to keep on the radar screen as we move into 2022. Could be good for the biotech sector:

Biomedical research may get a boost. Research in the early “translational” stage, when basic findings are applied to potential treatments, has long been notoriously difficult to finance. The pandemic has made matters worse. But relief may be on the way. While a bill to create government-backed bonds to finance private research — known as BioBonds— did not advance in the House of Representatives, the financial analyst behind the idea, Karen Petrou, is in talks with the White House, which is creating a new agencyto speed up research and cures. Called ARPA-Hand modeled after the Defense Advanced Research Projects Agency, the proposal has broad bipartisan support, according to a recent Morning Consult poll. So do BioBonds, Petrou said, adding that she hopes Congress will pass the measures early next year.nt).